Drug intelligence / Profile preview

hyaluronic acid + botulinum toxin type A

Development stage
Unknown
Lead developer
AbbVie
Modality
Recombinant Proteins and Enzymes
Administration
Intradermal, Intramuscular
01

Overview

A combination of **hyaluronic acid** (a glycosaminoglycan used as a dermal filler for soft tissue augmentation) and **botulinum toxin type A** (a neurotoxin protein that inhibits acetylcholine release at neuromuscular junctions), delivered together via injection for aesthetic and dermatological purposes, primarily **facial rejuvenation** (wrinkle reduction, skin texture and pore improvement). The combination leverages the muscle-relaxing action of botulinum toxin type A, which temporarily reduces dynamic wrinkles by blocking neuromuscular transmission, and the hydrating, volumizing, and skin-structural benefits of hyaluronic acid, which fills static wrinkles and restores facial volume. Studies consistently report **greater efficacy, longer duration of effect, smaller toxin doses, and improved patient satisfaction** compared to the use of either agent alone. The treatment is widely used in aesthetic medicine for facial rejuvenation, wrinkle reduction, and for improving acne-associated enlarged pores[1][2][3][4].

Other names
hyaluronic acid and botulinum toxin type Ahyaluronic acid plus botulinum toxin type A
02

Targets

α3β2 nAChR (α3β2 nicotinic receptor)SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on hyaluronic acid + botulinum toxin type A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyaluronic acid + botulinum toxin type A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call